<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p222" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_222{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_222{left:306px;bottom:30px;}
#t3_222{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_222{left:346px;bottom:30px;}
#t5_222{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_222{left:517px;bottom:30px;}
#t7_222{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_222{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_222{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_222{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_222{left:35px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#tc_222{left:35px;bottom:759px;letter-spacing:0.06px;word-spacing:0.13px;}
#td_222{left:35px;bottom:739px;letter-spacing:0.08px;word-spacing:0.11px;}
#te_222{left:35px;bottom:720px;word-spacing:0.18px;}
#tf_222{left:35px;bottom:700px;letter-spacing:0.15px;}
#tg_222{left:548px;bottom:700px;}
#th_222{left:35px;bottom:665px;letter-spacing:0.09px;word-spacing:-0.69px;}
#ti_222{left:35px;bottom:645px;letter-spacing:0.04px;word-spacing:0.15px;}
#tj_222{left:35px;bottom:625px;letter-spacing:0.06px;word-spacing:0.13px;}
#tk_222{left:35px;bottom:606px;letter-spacing:0.16px;}
#tl_222{left:396px;bottom:606px;}
#tm_222{left:35px;bottom:570px;letter-spacing:0.06px;word-spacing:-0.76px;}
#tn_222{left:35px;bottom:551px;letter-spacing:0.08px;word-spacing:0.11px;}
#to_222{left:35px;bottom:531px;letter-spacing:0.05px;word-spacing:0.14px;}
#tp_222{left:35px;bottom:512px;letter-spacing:0.02px;word-spacing:0.32px;}
#tq_222{left:35px;bottom:492px;letter-spacing:0.11px;word-spacing:0.08px;}
#tr_222{left:35px;bottom:473px;letter-spacing:-0.23px;word-spacing:1.63px;}
#ts_222{left:132px;bottom:473px;letter-spacing:0.16px;}
#tt_222{left:501px;bottom:473px;}
#tu_222{left:35px;bottom:437px;letter-spacing:0.18px;word-spacing:0.01px;}
#tv_222{left:35px;bottom:418px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tw_222{left:35px;bottom:398px;letter-spacing:0.04px;word-spacing:0.14px;}
#tx_222{left:35px;bottom:379px;letter-spacing:0.15px;}
#ty_222{left:395px;bottom:379px;}
#tz_222{left:35px;bottom:343px;letter-spacing:0.16px;word-spacing:-0.73px;}
#t10_222{left:35px;bottom:324px;letter-spacing:0.06px;word-spacing:0.12px;}
#t11_222{left:35px;bottom:304px;letter-spacing:0.09px;word-spacing:0.09px;}
#t12_222{left:35px;bottom:284px;letter-spacing:0.16px;}
#t13_222{left:405px;bottom:284px;}
#t14_222{left:35px;bottom:249px;letter-spacing:0.01px;word-spacing:-0.65px;}
#t15_222{left:35px;bottom:229px;letter-spacing:0.06px;word-spacing:0.13px;}
#t16_222{left:35px;bottom:210px;letter-spacing:0.09px;word-spacing:0.09px;}
#t17_222{left:35px;bottom:190px;letter-spacing:0.16px;}
#t18_222{left:396px;bottom:190px;}
#t19_222{left:35px;bottom:155px;letter-spacing:0.01px;word-spacing:-0.65px;}
#t1a_222{left:35px;bottom:135px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1b_222{left:35px;bottom:116px;letter-spacing:0.04px;word-spacing:-0.13px;}
#t1c_222{left:35px;bottom:96px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1d_222{left:35px;bottom:77px;letter-spacing:0.16px;}
#t1e_222{left:396px;bottom:77px;}
#t1f_222{left:618px;bottom:777px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1g_222{left:618px;bottom:759px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1h_222{left:618px;bottom:739px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1i_222{left:618px;bottom:720px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1j_222{left:618px;bottom:700px;letter-spacing:0.16px;}
#t1k_222{left:988px;bottom:700px;}
#t1l_222{left:618px;bottom:665px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1m_222{left:618px;bottom:645px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1n_222{left:618px;bottom:625px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1o_222{left:618px;bottom:606px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1p_222{left:618px;bottom:586px;letter-spacing:-0.38px;}
#t1q_222{left:642px;bottom:586px;letter-spacing:0.16px;}
#t1r_222{left:1011px;bottom:586px;}
#t1s_222{left:618px;bottom:551px;letter-spacing:0.07px;word-spacing:-0.82px;}
#t1t_222{left:618px;bottom:531px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1u_222{left:618px;bottom:512px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1v_222{left:618px;bottom:492px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1w_222{left:618px;bottom:473px;letter-spacing:0.16px;}
#t1x_222{left:988px;bottom:473px;}
#t1y_222{left:618px;bottom:437px;letter-spacing:0.05px;word-spacing:-0.76px;}
#t1z_222{left:618px;bottom:418px;letter-spacing:0.04px;word-spacing:0.15px;}
#t20_222{left:618px;bottom:398px;letter-spacing:0.03px;word-spacing:-0.54px;}
#t21_222{left:618px;bottom:379px;letter-spacing:0.06px;word-spacing:0.13px;}
#t22_222{left:618px;bottom:359px;letter-spacing:0.16px;}
#t23_222{left:988px;bottom:359px;}
#t24_222{left:618px;bottom:324px;letter-spacing:0.06px;word-spacing:0.12px;}
#t25_222{left:618px;bottom:304px;letter-spacing:0.03px;word-spacing:0.16px;}
#t26_222{left:618px;bottom:284px;letter-spacing:0.05px;word-spacing:0.14px;}
#t27_222{left:618px;bottom:266px;letter-spacing:0.15px;word-spacing:0.04px;}
#t28_222{left:618px;bottom:247px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t29_222{left:715px;bottom:247px;letter-spacing:0.16px;}
#t2a_222{left:1084px;bottom:247px;}
#t2b_222{left:618px;bottom:210px;letter-spacing:0.08px;word-spacing:-1.02px;}
#t2c_222{left:618px;bottom:190px;letter-spacing:0.12px;word-spacing:-0.89px;}
#t2d_222{left:618px;bottom:172px;letter-spacing:0.02px;word-spacing:0.16px;}
#t2e_222{left:618px;bottom:152px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2f_222{left:618px;bottom:133px;letter-spacing:0.16px;}
#t2g_222{left:979px;bottom:133px;}
#t2h_222{left:618px;bottom:96px;letter-spacing:0.09px;word-spacing:-0.63px;}
#t2i_222{left:618px;bottom:78px;letter-spacing:0.03px;word-spacing:0.16px;}
#t2j_222{left:618px;bottom:58px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2k_222{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_222{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_222{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_222{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_222{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_222{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_222{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_222{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts222" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg222Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg222" style="-webkit-user-select: none;"><object width="1210" height="935" data="222/222.svg" type="image/svg+xml" id="pdf222" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_222" class="t s0_222">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_222" class="t s1_222">© </span>
<span id="t3_222" class="t s0_222">(NCCN </span>
<span id="t4_222" class="t s1_222">© </span>
<span id="t5_222" class="t s0_222">), All rights reserved. NCCN Guidelines </span>
<span id="t6_222" class="t s1_222">® </span>
<span id="t7_222" class="t s0_222">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_222" class="t s2_222">NCCN Guidelines Version 4.2024 </span>
<span id="t9_222" class="t s2_222">Head and Neck Cancers </span>
<span id="ta_222" class="t s3_222">MS-81 </span>
<span id="tb_222" class="t s4_222">276. Bourhis J, Amand C, Pignon J-P. Update of MACH-NC (Meta- </span>
<span id="tc_222" class="t s4_222">Analysis of Chemotherapy in Head &amp; Neck Cancer) database focused on </span>
<span id="td_222" class="t s4_222">concomitant chemoradiotherapy [abstract]. J Clin Oncol 2004;22(Suppl </span>
<span id="te_222" class="t s4_222">14):Abstract 5505. Available at: </span>
<span id="tf_222" class="t s5_222">http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/5505</span><span id="tg_222" class="t s4_222">. </span>
<span id="th_222" class="t s4_222">277. Pignon JP, le Maitre A, Bourhis J. Meta-analyses of chemotherapy in </span>
<span id="ti_222" class="t s4_222">head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol </span>
<span id="tj_222" class="t s4_222">Phys 2007;69:S112-114. Available at: </span>
<span id="tk_222" class="t s5_222">http://www.ncbi.nlm.nih.gov/pubmed/17848275</span><span id="tl_222" class="t s4_222">. </span>
<span id="tm_222" class="t s4_222">278. De Felice F, Belgioia L, Alterio D, et al. Survival and toxicity of weekly </span>
<span id="tn_222" class="t s4_222">cisplatin chemoradiotherapy versus three-weekly cisplatin </span>
<span id="to_222" class="t s4_222">chemoradiotherapy for head and neck cancer: a systematic review and </span>
<span id="tp_222" class="t s4_222">meta-analysis endorsed by the Italian Association of Radiotherapy and </span>
<span id="tq_222" class="t s4_222">Clinical Oncology (AIRO). Crit Rev Oncol Hematol 2021;162:103345. </span>
<span id="tr_222" class="t s4_222">Available at: </span><span id="ts_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/33933569</span><span id="tt_222" class="t s4_222">. </span>
<span id="tu_222" class="t s4_222">279. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF- </span>
<span id="tv_222" class="t s4_222">alpha and EGFR protein in head and neck squamous cell carcinoma and </span>
<span id="tw_222" class="t s4_222">patient survival. J Natl Cancer Inst 1998;90:824-832. Available at: </span>
<span id="tx_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/9625170</span><span id="ty_222" class="t s4_222">. </span>
<span id="tz_222" class="t s4_222">280. Zhu X, Zhang F, Zhang W, et al. Prognostic role of epidermal growth </span>
<span id="t10_222" class="t s4_222">factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol </span>
<span id="t11_222" class="t s4_222">2013;108:387-397. Available at: </span>
<span id="t12_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/24038070</span><span id="t13_222" class="t s4_222">. </span>
<span id="t14_222" class="t s4_222">281. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for </span>
<span id="t15_222" class="t s4_222">squamous-cell carcinoma of the head and neck. N Engl J Med </span>
<span id="t16_222" class="t s4_222">2006;354:567-578. Available at: </span>
<span id="t17_222" class="t s5_222">http://www.ncbi.nlm.nih.gov/pubmed/16467544</span><span id="t18_222" class="t s4_222">. </span>
<span id="t19_222" class="t s4_222">282. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for </span>
<span id="t1a_222" class="t s4_222">locoregionally advanced head and neck cancer: 5-year survival data from </span>
<span id="t1b_222" class="t s4_222">a phase 3 randomised trial, and relation between cetuximab-induced rash </span>
<span id="t1c_222" class="t s4_222">and survival. Lancet Oncol 2010;11:21-28. Available at: </span>
<span id="t1d_222" class="t s5_222">http://www.ncbi.nlm.nih.gov/pubmed/19897418</span><span id="t1e_222" class="t s4_222">. </span>
<span id="t1f_222" class="t s4_222">283. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of </span>
<span id="t1g_222" class="t s4_222">concurrent accelerated radiation plus cisplatin with or without cetuximab </span>
<span id="t1h_222" class="t s4_222">for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol </span>
<span id="t1i_222" class="t s4_222">2014;32:2940-2950. Available at: </span>
<span id="t1j_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/25154822</span><span id="t1k_222" class="t s4_222">. </span>
<span id="t1l_222" class="t s4_222">284. Tao Y, Auperin A, Sire C, et al. Improved outcome by adding </span>
<span id="t1m_222" class="t s4_222">concurrent chemotherapy to cetuximab and radiotherapy for locally </span>
<span id="t1n_222" class="t s4_222">advanced head and neck carcinomas: results of the GORTEC 2007-01 </span>
<span id="t1o_222" class="t s4_222">phase III randomized trial. J Clin Oncol 2018:JCO2017762518. Available </span>
<span id="t1p_222" class="t s4_222">at: </span><span id="t1q_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/29878867</span><span id="t1r_222" class="t s4_222">. </span>
<span id="t1s_222" class="t s4_222">285. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or </span>
<span id="t1t_222" class="t s4_222">cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG </span>
<span id="t1u_222" class="t s4_222">Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. </span>
<span id="t1v_222" class="t s4_222">Lancet 2019;393:40-50. Available at: </span>
<span id="t1w_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/30449625</span><span id="t1x_222" class="t s4_222">. </span>
<span id="t1y_222" class="t s4_222">286. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin </span>
<span id="t1z_222" class="t s4_222">or cetuximab in low-risk human papillomavirus-positive oropharyngeal </span>
<span id="t20_222" class="t s4_222">cancer (De-ESCALaTE HPV): an open-label randomised controlled phase </span>
<span id="t21_222" class="t s4_222">3 trial. Lancet 2019;393:51-60. Available at: </span>
<span id="t22_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/30449623</span><span id="t23_222" class="t s4_222">. </span>
<span id="t24_222" class="t s4_222">287. Rischin D, King M, Kenny L, et al. Randomized trial of radiation </span>
<span id="t25_222" class="t s4_222">therapy with weekly cisplatin or cetuximab in low-risk HPV-associated </span>
<span id="t26_222" class="t s4_222">oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation </span>
<span id="t27_222" class="t s4_222">Oncology Group Study. Int J Radiat Oncol Biol Phys 2021;111:876-886. </span>
<span id="t28_222" class="t s4_222">Available at: </span><span id="t29_222" class="t s5_222">https://www.ncbi.nlm.nih.gov/pubmed/34098030</span><span id="t2a_222" class="t s4_222">. </span>
<span id="t2b_222" class="t s4_222">288. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG </span>
<span id="t2c_222" class="t s4_222">91-11: a comparison of three nonsurgical treatment strategies to preserve </span>
<span id="t2d_222" class="t s4_222">the larynx in patients with locally advanced larynx cancer. J Clin Oncol </span>
<span id="t2e_222" class="t s4_222">2013;31:845-852. Available at: </span>
<span id="t2f_222" class="t s5_222">http://www.ncbi.nlm.nih.gov/pubmed/23182993</span><span id="t2g_222" class="t s4_222">. </span>
<span id="t2h_222" class="t s4_222">289. Ko EC, Genden EM, Misiukiewicz K, et al. Toxicity profile and clinical </span>
<span id="t2i_222" class="t s4_222">outcomes in locally advanced head and neck cancer patients treated with </span>
<span id="t2j_222" class="t s4_222">induction chemotherapy prior to concurrent chemoradiation. Oncol Rep </span>
<span id="t2k_222" class="t s6_222">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
